Contact Sales Technical Support

Making Sense of Mitochondria Drug Discovery News Feature…read more

drug-discovery-news

CORK, Ireland & SHANGHAI, China—Biotechnology company Luxcel Biosciences Ltd. and HD Biosciences Co. Ltd., a preclinical drug discovery contract research organization (CRO), have entered a strategic partnership to co‐market and provide new assay technologies for preclinical drug safety services. Under the terms of the agreement, HDB will gain access to Luxcel’s state‐of‐the‐art assays and technologies for assessment of mitochondrial function, toxicity and metabolism.

Mitochondrial dysfunction is a major contributor to drug‐induced toxicity, postmarket drug withdrawal and black box warnings for hepatic and cardiac toxicity, according to Luxcel. A major focus of the collaboration is the Respirometric Screening Technology (RST/OCR) assay, originally developed by Luxcel in collaboration with Pfizer Inc.
Click logo to read full article…
partner